What you posted looks a lot like others I've seen posted almost...

What you posted looks a lot like others I've seen posted almost identical in fact, I suppose it's a company standard response that gets copy pasted here every so often.
so let me ask you this: if 3 cholesterol lowering drugs let's call them A, B & C all reduce 'bad' cholesterol by 30-40% (vs placebo) and drug D comes along and reduces bad cholesterol by only half that, you still reckon drug D results are "impressive"?. Somehow I doubt it. Yet you think DMX200 reducing proteinuria by 17% vs placebo (and 1% VS placebo in their diabetes kidney study) is impressive when other therapy classes have been shown to reduce it by twice as much in various types of proteinuric kidney diseases? Curious.
The question is not whether the 17% reduction vs placebo does potentially something to GFR, it's whether that "something" is going to be enough to meet the statistical success target they've set of at least 1.68 ml/min/year slope benefit (reference: DXB poster ASN 2022, DXB website), which looks ambitious to me.
Anyway DMX not the only kid on the block, I got sent this link to patent filed by chemocentryx for CCR2 inhibitor for treatment of FSGS used alone or in combination with RAS blockers or endothelin antagonists in China. I assume it's genuine.
https://patents.google.com/patent/CN111417389A/en